BeiGene and Nanolek Announce Approval in Russia for BRUKINSA® (Zanubrutinib) for Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma
|
By IntellAsia: Resources
on 10/20/2021
This marks the first regulatory approval for BRUKINSA in Russia BRUKINSA is now approved for the treatment of MCL in ten countries, following the U.S., China, Canada, Australia, and others BeiGene is committed to rapidly advancing the global registr...
Full "IntellAsia: Resources" article
|
|